How Should Multiple Models of Medical Dressings Be Grouped for Overseas Registration?

Direct answer: Multiple models of medical dressings may be grouped into one overseas registration application when they can be justified as the same product family or registration unit, with consistent regulatory classification, risk level, intended use, mechanism of action, materials, sterilization method, and critical performance characteristics. The grouping must be supported by a model genealogy, difference analysis matrix, model coverage statement, shared technical file, risk management report, performance verification summary, clinical evaluation or exemption rationale, and labeling and instructions for use difference explanation. If models differ materially in these dimensions, they should be split into separate registration units.

Published: 2026-09-03 19:41; Updated: 2026-09-03 19:41

This FAQ addresses the priority questions that companies need to resolve in international medical device registration, documentation preparation, compliance pathways, and post-market maintenance.

Content structure

• Key summary
• Applicable scenarios and core questions
• Registration assessment logic
• Documentation and evidence
• Common errors
• Company preparation checklist
• Aimeili regulatory interpretation and business impact
• Common follow-up questions
• Continue reading
• Applicable boundary

Key summary

For medical dressings registered overseas, grouping multiple models into one application is a key step to shorten timelines and reduce costs, but incorrect grouping may lead to deficiency letters or registration failure. Companies should first determine whether the target country regulates the product as a medical device, and then determine the registration subject according to risk level and registration pathway. Models can usually be divided into a product family based on structure and composition, mechanism of action, intended use, raw materials, sterilization method, and critical performance indicators. However, grouping feasibility must be confirmed against the guidance of the specific country or region, such as GHWP member states, Southeast Asia, the Middle East, and Latin America.

For registration, companies must prepare a difference analysis matrix, model coverage statement, shared technical file, risk management report, performance verification summary, clinical evaluation or exemption basis, and labeling and instructions for use difference explanation. Common risks include mixing models across categories, using sales models instead of technical models, ignoring the impact of the local agent on grouping and certificate control, and arbitrarily expanding model coverage so that stability or biocompatibility data are insufficient. After market launch, companies must also maintain changes, renewals, and adverse event reporting for each model within the group. Early in the project, companies should prioritize mapping the model genealogy, consult local regulatory requirements, and establish the grouping logic and evidence chain.

Applicable scenarios and core questions

When medical dressing companies plan to enter overseas markets, they often face a large number of product models and fragmented specifications. For example, the same wound dressing may include products with different sizes, backing materials, adhesive formulations, or sterilization methods, and may even cover different categories such as absorbent dressings, non-absorbent dressings, and antibacterial dressings. If each model is registered separately, registration fees, testing time, and administrative burden will multiply, seriously delaying the product launch plan.

The core objective of multi-model grouping is to combine models with similar technical characteristics, intended use, and risk levels into the same registration unit without sacrificing regulatory safety and effectiveness, and to use the technical file of a representative model to cover the entire family, thereby obtaining market access authorization that covers multiple models. However, grouping is not a simple merger of models. Companies need to establish clear grouping logic and a complete evidence chain; otherwise, it is very easy for reviewers to question the grouping, leading to deficiencies, additional requests, or even refusal of registration.

This article is intended for medical device manufacturers, CRO regulatory personnel, and quality and regulatory affairs leads. It systematically explains the assessment logic, documentation preparation, common errors, and action checklist for grouping multiple models of medical dressings in overseas registration, helping companies reduce inefficient duplication of work and lower the risk of overseas registration failure caused by unclear model grouping.

Registration assessment logic

Step 1: Confirm whether the target country or region regulates medical dressings as medical devices

Although most countries and regions regulate dressings intended for wound covering, exudate absorption, hemostasis, and postoperative care as medical devices, some products may be classified as cosmetics, ordinary articles, or drugs. Examples include adhesive bandages used only for non-medical purposes or dressings containing only pharmaceutical ingredients. Companies need to review the target country regulator website, product classification database, or seek a preliminary opinion from a local regulatory agent. They should not assume that filing can be based on domestic classification.

Step 2: Determine the product risk level based on intended use, mechanism of action, and duration of use

Medical dressings are usually low-risk or lower-medium-risk products, such as Class I or Class IIa, but in some countries they may be classified as Class IIb, especially when the dressing claims antibacterial, healing-promoting, or absorbable functions. Companies must accurately translate the product description, mechanism of action, and functional claims, and map them to the target country classification rules. They should not simply reuse NMPA classification information.

Step 3: Determine the registration pathway and application subject

For GHWP member states, Southeast Asia, and other markets, the applicant is often required to be a locally registered legal entity, such as a local manufacturer, importer, or authorized representative. In multi-model grouping, the local agent is responsible for the model list in the certificate and future changes. Therefore, the professionalism and stability of the agent are critical.

Step 4: Assess the reusability of existing technical documentation

Companies should review the technical files, test reports, risk management documents, and clinical data corresponding to existing NMPA registration certificates, CE certificates, FDA 510(k) clearances, ISO 13485 certificates, or MDSAP certificates, and analyze whether these materials cover all items required by the target country. Because testing standards, label languages, and biocompatibility evaluation requirements differ across countries, even if the core technical file can be reused, localization conversion and gap analysis are still required.

Step 5: Determine the grouping unit and draft the difference analysis document

It is recommended to use a product family or model series as the logical unit and compare all models to be registered by structure and composition, raw materials, sterilization method, mechanism of action, intended use, and critical performance parameters. If the models are highly similar in these dimensions and have the same risk level, they can be submitted as the same registration unit. If there are significant differences, they should be split into different registration units and must not be forced into one group.

Documentation and evidence

When preparing documentation for multi-model grouping, companies must provide a clear product list and grouping statement. The documents should at least include a naming rule table for each model and specification, avoiding confusion caused by different sales names or overseas trade names. Regulatory authorities usually require that the models in the submission be consistent with the technical file, labels, instructions for use, and physical product.

A difference analysis matrix must be submitted. This matrix should compare design parameters, raw material composition, sterilization method, dimensional differences, packaging format, and performance indicators model by model, to demonstrate that the safety and effectiveness of the models within the same registration unit are sufficiently covered. For parameters that differ greatly but have no substantial impact on safety and effectiveness, the risk management report and verification data should explain that they have been adequately assessed.

The core technical file usually does not need to be submitted repeatedly for every model, but a complete technical report for a representative model should be provided, including product description, design verification, biocompatibility evaluation, stability studies, sterilization validation, and package integrity simulated transport testing. On this basis, the rationale for coverage by the representative model should be justified, explaining that when the representative model represents the most stringent performance, most complex structure, or highest risk, its data can be extended to other derivative models.

Labels and instructions for use must provide identifiable information for all models. If models differ in size, dressing structure, or applicable body sites for indications, this should be explained through acceptable labeling methods, such as size ranges, comparison tables, or a statement in the instructions for use that other models are listed in the product list. The target country regulator will not accept vague statements that models differ but the instructions for use are completely identical. Companies need to provide appropriate descriptions of the differences.

Local agent agreements, letters of authorization, quality system certificates, and post-market surveillance plans are also required. Although medical dressings are relatively low risk, adverse event reporting, product tracing, and vigilance systems after market launch must still have clear responsibility allocation. When registering in GHWP member states, Southeast Asia, the Middle East, or Latin America, common deficiency requests are precisely the lack of local agent confirmation of model coverage or post-market commitment documents.

If the target country regulations allow the use of clinical data from a previous generation product or an equivalence argument with a similar marketed product, companies should prepare a clinical evaluation report or exemption basis. Medical dressings can often complete clinical evaluation through compliance with recognized standards, accumulated clinical experience, and historical safety data. In grouped submissions, the clinical performance of all models is not necessarily completely consistent, and additional literature searches or failure mode analyses may be needed to explain this.

Common errors

• Listing all products that differ only in size but have completely identical structural design and raw materials without establishing the concept of a model family, missing the opportunity for combined submission and causing wasted cost and time.
• Failing to assess according to the target country classification and regulatory logic and directly copying the model list from the NMPA classification certificate, causing some models to be identified by reviewers as belonging to different risk categories and forcing split submissions.
• Mixing sales names, model codes, and internal R and D models, so that submitted documents are inconsistent with the actual product, often triggering deficiency letters.
• Attempting to arbitrarily include models with different sterilization methods, such as ethylene oxide sterilization, electron beam sterilization, and steam sterilization, in the same registration unit without providing sufficient evidence of sterilization process equivalence.
• Ignoring classification or performance requirement changes caused by special functions such as antibacterial, silver-containing, alginate, or hydrocolloid products, and mixing a model containing an active ingredient or a drug-device combination into an ordinary dressing family.
• Failing to clearly define the authorization scope of the local agent, so the agent cannot be responsible for updating and changing the grouped list, causing problems during subsequent registration renewal.
• Not adequately preparing performance comparison data for multiple models and only providing full reports for a representative model, while the reviewer requests raw data for certain critical indicators for all models, leaving the company unable to respond quickly.
• Labels and instructions for use failing to mark models and specifications according to the target country language and format requirements, with missing labels or translation differences, resulting in a finding of non-compliant labeling.

Company preparation checklist

• Map all existing and planned medical dressing models worldwide and establish a unified master model list. Fields should include product name, model code, sales name, size, raw materials, structure, sterilization method, packaging, intended use, and risk level.
• Clarify the regulatory classification and registration pathway of the target country. Use historical registration information in China NMPA, EU CE, US FDA, or other markets as reference, but not as the sole basis for judgment.
• Form a cross-functional team including regulatory, R and D, quality, and marketing personnel to complete the product model difference analysis matrix and identify model groups that can be combined and those that cannot.
• Confirm the qualifications and authorization scope of the local agent, sign an agreement, and specify the agent responsibilities in grouped submission, post-market changes, renewal, and adverse event reporting.
• Review existing test reports and risk management documents in NMPA registration certificates, CE technical files, FDA files, or ISO 13485 system documents in advance, and mark which must be reissued and which can be used after notarized translation.
• For each model family to be submitted, determine the representative model and conduct complete performance, biocompatibility, sterilization validation, and stability studies for the representative model. For non-representative models, prepare difference explanations and risk assessments.
• Create label, instructions for use, and packaging samples that meet the target country language and regulatory requirements, ensuring that all actually marketed models can be clearly matched in the coverage list.
• Establish standard operating procedures for post-market surveillance and adverse event reporting, and assign a dedicated person or engage a CI/RA service provider as the responsible person at the EU or member state level to meet post-registration continuation obligations.

Aimeili regulatory interpretation and business impact

After many years of consulting on overseas registration of medical dressings, we have seen that the most common misjudgment by companies is equating the same production line with the same registration unit. Many companies assume that as long as a model is listed in an existing domestic registration certificate, it can naturally be submitted overseas together, and they even ask the agent to submit the domestic certificate model list unchanged. This ultimately leads reviewers to require splitting because of substantial differences between models. The original one-time submission plan becomes multiple rounds of deficiency responses, extending the timeline by more than six months.

Early in the project, we recommend that companies first conduct a model genealogy review and grouping feasibility analysis. Do not wait until submission preparation to discuss which models can be covered. Instead, when confirming overseas intentions, study the target country classification rules, grouping guidance, and technical requirements clearly. For example, some Southeast Asian countries are very strict about the selection of representative models when accepting family registration and require proof that the model represents the worst-case condition. Some Middle Eastern countries also require a certificate of free sale from the country of origin and commitments for all changes in the model list. These early judgments can significantly reduce subsequent risks.

Regarding document reuse, ISO 13485 system documents, test reports, risk management documents, and non-clinical study data from CE or FDA submissions can usually be converted reasonably for multi-country submissions, but this is absolutely not simple copy-and-paste. For example, biocompatibility data evaluation standards may reference the latest version of ISO 10993-1. If the target country adopts an older version or requires additional reference to GB/T standards, a conformity check must be conducted again. Instructions for use, warnings, and indication wording must be fully localized and cannot simply be translated and submitted.

The local agent is not merely a post office for submitting documents; it is also an important link in certificate control. When multiple models are registered under one certificate, if you later add sizes, modify labels, or change raw material suppliers, you need to submit change applications through the local agent. If the agent is unstable or unfamiliar with regulations, changes may not be made in time, causing products already on sale to fall outside the certificate scope. Companies must treat the agent as a long-term regulatory partner, not a one-time procurement service.

Another major difficulty in multi-country registration is that regulatory authorities do not have completely consistent requirements, and each country may raise different deficiency comments on grouping. Our project experience shows that as long as companies conduct detailed difference analysis, maintain clear logic, and form a complete evidence chain around safety equivalence, they can reduce repeated organization and repeated deficiency responses across countries. Most deficiencies originate from incomplete original documentation rather than serious defects in the product itself. Therefore, spending time early to build a unified technical file framework and review checklist will save companies substantial later costs.

Common follow-up questions

Can models in the same product series with multiple optional sterilization methods be placed in the same registration unit?

When sterilization methods differ but all can ensure that the product achieves the expected safety and performance, they can be treated as derivative models of the same registration unit, but validation data must be provided on the equivalence of different sterilization methods with respect to material performance, package integrity, and residues. Usually, the most unfavorable sterilization process should be selected as the representative model for justification, and the key process parameters and product validation results of the other sterilization processes should be explained. If the reviewer considers that different sterilization methods cause unacceptable differences in product performance, the models must be split into separate registration units.

If one model of a medical dressing contains an active substance such as silver ions, can it be grouped with ordinary dressings?

A dressing containing antibacterial agents, silver ions, or other active ingredients is often classified independently or requires additional biological and clinical evaluation because its mechanism of action, intended use, and risk characteristics are different. It is generally not recommended to mix it in the same registration unit as traditional dressings without active ingredients, unless the active substance release is extremely low and the regulatory guidance clearly allows it to be covered as the same product family. The prudent approach is to group it separately and submit it separately, avoiding the impact of the review requirements for an individual variant on the overall registration progress.

If a model is sold only in a few countries, can a grouped application cover its marketing authorization?

This depends on the grouping coverage scope of the target country. If the model has little difference from the actually submitted representative model in structure and composition, raw materials, sterilization method, and performance requirements, and it is included in the model coverage table, it can usually obtain marketing authorization together. However, if the model is a special specification only for a specific market and may not meet local general requirements or labeling guidance, it should not simply rely on coverage. It is recommended to decide according to the specific guidance of that country whether to include it in the coverage or submit it separately. In any case, the certificate must clearly list the covered models, and a model not listed must not be claimed to be within the certificate scope for sale.

Continue reading

Previous: None. Next: How to Handle Inconsistencies in Quality System Evidence for Overseas Registration of Disinfection and Sterilization Equipment?

Recommended reading

• How Should Performance Verification Documentation Be Prepared for Overseas Registration of Medical Dressings?
• How Should the ISO 13485 Certificate Be Used for Overseas Registration of Medical Dressings?
• How Should Product Classification Be Determined for Overseas Registration of Medical Dressings?
• How to Handle Inconsistencies in Quality System Evidence for Overseas Registration of Disinfection and Sterilization Equipment?
• What Are the Risk Management Documentation Requirements for Overseas Registration of Medical Dressings?
• How Should Performance Verification Documentation Be Prepared for Overseas Registration of Disinfection and Sterilization Equipment?

Return to FAQ Center | News | Contact Aimeili

Content review and applicable boundary

Content author: Aimeili Regulatory Editorial Team

Professional review: Aimeili Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory agencies, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are used only as supplementary judgment.

Applicable boundary: This article is for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target country regulator, testing conclusions, or legal advice.

Source note: Compiled from the Aimeili Regulatory Affairs Practice Question Bank, the Medical Device International Registration Knowledge Base, and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country regulator and the product documentation.